Equitec Proprietary Markets’s Novavax NVAX Stock Holding History

Equitec Proprietary Markets’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,300	Closed	-$187K	–	228
2022 Q3	$187K	Buy	10,300 +10,200	+10,200%	+$442K	0.05%	94
2022 Q2	$5K	Buy	+100	New	+$5.18K	﹤0.01%	203

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIG

Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Equitec Proprietary Markets's NVAX Position: Q4 2022 in Review

Equitec Proprietary Markets sold out of Novavax (NVAX) in Q4 2022, closing a stake of 10,300 shares — an estimated $187K sold.

Equitec Proprietary Markets first reported a position in NVAX in Q2 2022 and held it in 2 quarters. The position peaked at $187K in Q3 2022. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

Equitec Proprietary Markets reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
Equitec Proprietary Markets sold 10,300 Novavax shares in Q4 2022, an estimated $187K.
Equitec Proprietary Markets first reported a position in Novavax in Q2 2022 and held it in 2 quarters.
Equitec Proprietary Markets's Novavax position peaked at $187K in Q3 2022.
252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Equitec Proprietary Markets's 13F filing for Q4 2022, filed 31 Jan 2023.